Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells $84,739.35 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 1,185 shares of Liquidia stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $84,739.35. Following the completion of the transaction, the insider directly owned 65,947 shares of the company’s stock, valued at approximately $4,715,869.97. This represents a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sanjeev Khindri also recently made the following trade(s):

• On Monday, June 8th, Sanjeev Khindri sold 4,134 shares of Liquidia stock. The stock was sold at an average price of $65.46, for a total transaction of $270,611.64.

Liquidia Stock Up 7.4%

Shares of NASDAQ LQDA traded up $5.28 during midday trading on Tuesday, hitting $76.49. The company’s stock had a trading volume of 1,153,916 shares, compared to its average volume of 2,219,263. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm has a market capitalization of $6.80 billion, a price-to-earnings ratio of 546.40 and a beta of 0.55. The business’s fifty day simple moving average is $66.37 and its two-hundred day simple moving average is $47.52. Liquidia Corporation has a 1 year low of $14.04 and a 1 year high of $82.96.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm’s revenue was up 4187.1% on a year-over-year basis. On average, equities analysts predict that Liquidia Corporation will post 3.02 EPS for the current year.

Institutional Trading of Liquidia

Institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Liquidia in the 4th quarter valued at $25,000. NewEdge Advisors LLC acquired a new stake in Liquidia during the 2nd quarter worth $25,000. FNY Investment Advisers LLC purchased a new stake in Liquidia in the third quarter valued at $34,000. Covestor Ltd lifted its position in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Liquidia by 281.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after acquiring an additional 4,927 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

LQDA has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. BTIG Research boosted their target price on Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Bank of America restated a “neutral” rating and set a $79.00 price target (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Finally, Oppenheimer set a $75.00 price target on Liquidia in a research report on Friday, June 5th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Liquidia presently has a consensus rating of “Moderate Buy” and an average target price of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).